Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
Key claim: INCB057643, a BET bromodomain inhibitor, is being evaluated for safety, tolerability, and preliminary efficacy as monotherapy or in combination with ruxolitinib in patients with myelofibrosis and other advanced myeloid neoplasms.
Abstract
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of INCB057643 as monotherapy or combination with ruxolitinib for participants with myelofibrosis (MF) and other myeloid neoplasms.
Why this matters
BET bromodomain inhibition is an emerging epigenetic strategy in MPNs, and INCB057643 joins a crowded pipeline of agents (selinexor, roginolisib, iadademstat, navitoclax-class drugs) being layered onto ruxolitinib to deepen responses in PMF. Tracking this trial on the PMF page helps map the subtype-specific combination landscape and clarifies which mechanistic classes are being prioritized for ruxolitinib-suboptimal or advanced-phase disease.